Epicutaneous Dry Antigen Patch for TH1 Immune Response

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional vaccination methods require multiple administrations, often with adjuvants and liquid preparations, which can be inconvenient and do not effectively control or analyze the immune response, particularly in inducing a strong TH1-oriented immune response.

Innovation Solution

The method involves applying a dry, non-adjuvanted antigen preparation to intact skin using an occlusive patch device, which amplifies and TH1-orientes a pre-existing immune response, either as a boost following conventional vaccination or as a standalone treatment, to enhance immunity against pathogens.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If conventional vaccination uses liquid preparations with adjuvants and multiple administrations, then immune response can be induced, but convenience is reduced and immune response orientation (TH1) is not effectively controlled

Engineering Contradiction:
Improveconvenience of vaccinationVSAvoidimmune response orientation (TH1)
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The invention changes the physical state of the antigen preparation from liquid to dry form, and modifies the administration route from parenteral to epicutaneous application. This parameter change eliminates the need for adjuvants and multiple injections while effectively inducing TH1-oriented immune response through the skin's immune-competent cells

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention extracts and eliminates the adjuvant component from the vaccination system by using dry antigen preparations applied to the skin. The skin itself serves as the delivery system and immune activator, removing the need for separate adjuvant substances while maintaining effective TH1 response induction

Inventive Principle:
Principle #2Taking out (Extraction)

2Reliability

If multiple priming and boost administrations are used in conventional vaccination, then immune response is amplified, but the number of administrations and time required increases

Engineering Contradiction:
Improveimmune response amplificationVSAvoidtime for multiple administrations
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The dry epicutaneous antigen preparation is designed to provide both priming and boosting effects in a single application or minimal applications. The formulation and delivery method are preliminarily optimized to ensure sufficient antigen exposure and immune activation without requiring multiple separate administration sessions

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention merges the functions of multiple priming and boost administrations into a single epicutaneous application protocol. The dry antigen preparation combines the immunogenic properties needed for both initial immune activation and subsequent amplification in one convenient treatment

Inventive Principle:
Principle #5Merging (Combining)

3Reliability

If skin pre-treatment and liquid adjuvanted preparations are used for transcutaneous immunization, then immune response is provoked, but the system becomes more complex and less convenient

Engineering Contradiction:
Improveimmune response inductionVSAvoidcomplexity of skin preparation and application system
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The skin's natural structure and immune-competent cells serve the dual function of both delivery vehicle and immune activator. No external adjuvants or pre-treatment procedures are needed - the skin itself performs the work of antigen delivery and immune system activation, simplifying the overall system

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The invention removes the need for skin pre-treatment procedures (such as tape stripping or chemical preparation) and eliminates adjuvant substances from the system. Only the dry antigen preparation and simple skin application remain, dramatically reducing system complexity while maintaining effective immune response induction

Inventive Principle:
Principle #2Taking out (Extraction)

Data Source

PatentEP2547358B1Method of vaccination
Publication Date: 2016.11.02 DBV TECH INC
  • EP2547358B1 patent drawingFigure 1
  • EP2547358B1 patent drawingFigure 2
  • EP2547358B1 patent drawingFigure 3

AI summary

The present invention relates to methods for vaccination of a subject. Particularly, the present invention discloses the use of skin antigen application to amplify a pre-existing immunity against a selected pathogen in a subject. The present invention discloses the use of skin application in combination with conventional vaccination or priming for immunization or vaccination of a subject against a selected pathogen.